Clinical Trial: Irinotecan Liposome(II) Combined with Ivonescimab As Second-line Treatment for Small Cell Lung Cancer : a Prospective, Single-arm, Multicenter Clinical Study

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820762) titled 'Irinotecan Liposome(II) Combined with Ivonescimab As Second-line Treatment for Small Cell Lung Cancer : a Prospective, Single-arm, Multicenter Clinical Study' on Feb. 05.

Brief Summary: This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: SCLC

Intervention: DRUG: irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity

Drug: ivonescimab 20mg/kg, IV, D1, Q3W

Other Names:

AK1...